

Remarks

This Paper is responsive to the Office Action mailed October 15, 2001 (Paper No. 4).
Entry of this Paper is respectfully requested.

Claims

Claims 2-10 were pending. Claims 2-10 were subject to a six (6) way Restriction Requirement.

Claims 2-10 have been canceled without prejudice or disclaimer of the subject matter therein. Moreover, Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

New claims 11-22 have been added. No new matter is added.

It is believed that entry of this Amendment will not require payment of any additional claim fees. Notwithstanding, Applicants hereby authorize the Commissioner to charge any additional claim fees deemed required by entry of this Amendment to Deposit Account No. 50-0258.

Support

Support for the new claims is either apparent or is as described in the text below. Specifically, support for the recitation "wherein the nucleic acid sequence is not genomic DNA" may be found in the specification at, for example, page 6, lines 25-30. No new matter is added.

Election/Restriction

Applicants hereby elect to prosecute Group I (claims 2 and 5-7), without traverse. While the election of Group I is without traverse, Applicants reserve the right to traverse restriction requirements between the other asserted claim groups.

Serial No.: 09/749,972
Group Art Unit: 1652

FEE DEFICIENCY

- ☒ If an extension of time is deemed required for consideration of this paper, please consider this paper to comprise a petition for such an extension of time; The Commissioner is hereby authorized to charge the fee for any such extension to Deposit Account No. 50-0258.
- and/or**
- ☒ If any additional fee is required for consideration of this paper, please charge Account No. 50-0258.

Closing Remarks

Entry of this Paper and allowance of the pending claims are respectfully requested.

Respectfully submitted,



Thomas S. Deibert
Registration No. 40,984
Attorney for Applicants

DECHERT PRICE & RHOADS
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Fax: (609) 620-3259
Attn: Thomas S. Deibert, Esq.
(609) 620-3231

Detail of claim amendments

- 11. An isolated polynucleotide comprising a nucleic acid sequence, wherein the nucleic acid sequence comprises SEQ ID NO:1 and wherein the nucleic acid sequence is not genomic DNA.
- 12. A vector comprising the isolated polynucleotide of claim 11.
- 13. An isolated host cell comprising the vector of claim 12.
- 14. A process for producing a polypeptide comprising culturing the host cell of claim 13 to produce a polypeptide, wherein the polypeptide comprises SEQ ID NO:2.
- 15. An isolated polynucleotide comprising a nucleic acid sequence, wherein the nucleic acid sequence encodes a polypeptide comprising SEQ ID NO:2, wherein the nucleic acid sequence is not genomic DNA.
- 16. A vector comprising the isolated polynucleotide of claim 15.
- 17. An isolated host cell comprising the vector of claim 16.
- 18. A process for producing a polypeptide comprising culturing the host cell of claim 17 to produce the polypeptide, wherein the polypeptide comprises SEQ ID NO:2.
- 19. An isolated polynucleotide comprising a nucleic acid sequence, wherein the nucleic acid sequence encodes a polypeptide consisting of SEQ ID NO:2, wherein the nucleic acid sequence is not genomic DNA.
- 20. A vector comprising the isolated polynucleotide of claim 19.

Serial No.: 09/749,972

Group Art Unit: 1652

-- 21. An isolated host cell comprising the vector of claim 20.

-- 22. A process for producing a polypeptide comprising culturing the host cell of claim 21 to produce the polypeptide, wherein the polypeptide consists of SEQ ID NO:2. --